Bipolar Disorder

This book could be a resource for your patients with bipolar disorder…

From research updates on at-home ketamine use to the effects of comorbid depression and anxiety on insomnia treatment, here are highlights from the week in Psychiatric Times.

Gestational and neonatal risk factors for bipolar disorder? Researchers investigated these associations in a nationwide cohort with register-based data.

Neuroimaging could help predict clinical response to treatment in bipolar depression.

PME affects many women, yet it remains under-recognized in clinical practice and in research.

In Part III of this series, an expert discusses the key differences between cyclothymia and borderline personality disorder, along with treatment considerations for cyclothymia.

In Part II of this series, an expert discusses cyclothymia and mood temperament in children and adolescents.

In Part I of this new series, an expert provides an overview of cyclothymia and mood temperaments.

A look at the theme for the 2023 American Psychiatric Association Annual Meeting.

From connections between bvFTD and primary psychiatric disorders to the impact of posttraumatic neuroendocrine dysfunction on recovery, here are highlights from the week in Psychiatric Times.

Aripiprazole will be the first 2-month LAI antipsychotic indicated for both the treatment of schizophrenia and the maintenance treatment of bipolar I disorder in the United States.

From to co-occurring substance use and eating disorders to treatment options for OCD, here are highlights from the week in Psychiatric Times.

What is the current role of lithium?

From gut microbiota and SSRIs in MDD to nonpharmacological interventions following TBI, here are highlights from the week in Psychiatric Times.

The experts weighed in on a wide variety of psychiatric issues for the March 2023 issue of Psychiatric Times.

March 30 is World Bipolar Day, a day dedicated to raising awareness and eliminating stigma surrounding bipolar disorders. Learn more about bipolar disorders by catching up on the latest bipolar research in Psychiatric Times®.

New results for a study evaluating lumateperone.

What are the psychiatric and non-psychiatric correlates of tobacco smoking status in bipolar disorders? Researchers investigated these associations in a large patient cohort.

An update from a patient we learned about a year ago.

From an update on at-home ketamine therapy to the psychopharmacologic treatment of bipolar depression, here are highlights from the week in Psychiatric Times.

What is the best evidence-based medication treatment for acute bipolar II depression?

Caffeine use is higher in smokers and in adults with serious mental illness. How does this impact patients with bipolar disorder and schizophrenia?

Catch up on the latest CMEs in Psychiatric Times.

Researchers performed a nationwide register-based cohort study of patients treated with lithium in Finland.

Lithium: what’s its history and where do we still need more information?

Catatonia: learn more about how to best diagnose early.

New approval for schizophrenia and bipolar I disorder.

“The sooner you can recognize and diagnose bipolar, the sooner you can institute effective evidence-based treatments.”

Data on the effects of discontinuing lithium on renal function are scarce and conflicting. A new study exploring these effects may aid in the clinical decision-making process.

From the effects of caffeine on smokers with schizophrenia and bipolar disorder to the initiation of a trial for a new ADHD medication, here are highlights from the week in Psychiatric Times.